National and Kapodistrian University of Athens
Μελέτη της επίδρασης της οικογένειας του EGFR στον καρκίνο του μαστού
Abstract
dc:descriptionIntroduction: HER-2 is overexpressed in 20–30% of breast cancer (BC), indicating poor prognosis. RANK downstream signaling pathways play a central role in BC. RANKL/RANK signaling pathway is implicated in HER-2(+) BC. The molecular mechanism of this implication remains to be elucidated. Aim: The aim of the dissertation is to investigate the implication of RANK receptor and NF-κB signaling pathway in the tumorigenesis of HER-2 (+) breast cancer (BC). Also, we tried to elucidate the molecular mechanisms underlying the regulation of RANKL/ RANK signaling by members of the EGFR family through putative physical interaction, affecting basic cellular properties. Finally, we examined the in vitro impact of the combined inhibition of RANK and HER-2 receptors in cancer cell development, which introduces new therapeutic strategies. Material and Methods: Human BC cell lines SKBR3, BT474, MCF7, MDA-MB-453 were used. The expression of RANK and RANKL was evaluated using RT-PCR, Western-Blot and immunofluorescence. The interaction between RANK and HER-2 was detected using Proximity Ligation Assay (PLA) which enables the visualization of interacting proteins. NF-κB pathway activation was studied using Western-Blot. The inhibitors trastuzumab (T), pertuzumab (P) and denosumab (D) of both pathways were used. The functional assays to study migration, apoptosis and proliferation were applied. Proliferation was evaluated using ΧTT and clonogenic assay, migration capacity via Scratch-Wound Healing Assay and apoptosis using flow cytometry analysis of annexin V and Propidium Iodite (PI) cell staining. Results: Cell lines express RANK and RANKL. RANK receptor dimerizes with EGFR family members. RANK / HER-2 dimer number was found associated with HER-2 expression (SKBR3: 5.4, BT-474: 8.2, MCF7: 0.7, MDA-MB-453: 0.3). RANK / HER-2 dimers were decreased in the presence of the inhibitors D, T and P, while they were increased after RANKL (R) treatment in SKBR3 cells (m:5.4, D:1.2, T:1.9, DT:0.6, TP:1, DTP:0.4, R:11.8,) and BT-474 (m:8.2, D:3.1, T:4.3, DT:0.7, TP:3.4, DTP:3.2, R:11.6). Combination targeting of SKBR3 cells further decreased NF-κB pathway activation compared to single targeting experiments. In SKBR3, RANKL and HER-2 blockage resulted in reduced cell proliferation, increased apoptosis and lower metastatic potential compared to mock cells (m) and reversed values upon RANKL presence. The combination treatment of SKBR3 cells with D, T and P had an advantage in functional traits compared to single targeting. Denosumab suppressed NF-κB signaling and diminished proliferation rate in MDA-MB-453 cells. MCF7 did not correspond to inhibitors. Conclusions: The results indicate a novel physical and molecular association between HER-2 and RANK pathways that affects HER-2 (+) BC growth. Our data suggest that the combination of anti-HER-2 agents and RANKL inhibitors have a potential direct anti-tumor effect and should be further tested in certain BC patients.
Degree
thesis:*- Grantor dc:publisher
- National and Kapodistrian University of Athens
- Year dc:date
- 2019
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Ζοι, Ilianna
- Ζώη, Ηλιάννα
Subjects
dc:subject × 16Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/46740